GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Who Regulates Stem Cell Therapy in Japan?

Japan’s Ministry of Health, Labour and Welfare (MHLW) oversees stem cell therapy under two main legal frameworks. The Pharmaceuticals and Medical Devices Agency (PMDA) reviews manufactured regenerative medical products; the Minister of MHLW grants marketing approval. Clinic procedures under the safety law require certified committee review and a provision plan submitted to MHLW. A filed plan is not product approval or proof of clinical benefit. 0003

Two Laws, Two Jobs

The two tracks divide oversight by activity, with MHLW involved in both. The current setup dates to November 2014. The safety law itself took effect on 25 November 2014.0000150542_00016 Then an update kicked in on 31 May 2025.0000150542_00016 It pulled gene therapy without cell processing into the highest-risk group, and plans now have to explain how their scientific validity was assessed.Saisei_top_00005 Regenerative medicine is a broader legal category than stem cell therapy.0003

Who Regulates Stem Cell Therapy in Japan?
Question Safety-law track Product-approval track
Law Act on the Safety of Regenerative Medicine (ASRM) Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act)
Covers Medical use of processed cells in hospitals and clinics, including treatment and research carried out as medical care Manufactured regenerative medical products a company wants to sell
Who reviews A certified committee first, then a provision plan filed with MHLW PMDA review, with marketing approval granted by the Minister of MHLW
What the record means Required review and plan submission for a named procedure; these are not product approval or a guarantee of overall compliance One specific product met quality, safety, and efficacy requirements for one defined use

Who Does What

Health Ministry

MHLW writes the rules for both tracks. It collects the provision plans from clinics, puts information out for patients, and can step in with orders when the safety law is broken.

If you are checking one specific offer, start with MHLW’s own pages. They explain the filing process, the Class I, II, and III risk classes, and the published treatment information anyone can look up.Plan For a clinic procedure under the safety law, ask whether “registered” refers to a provision plan submitted to MHLW.Plan Skipping that filing and offering treatment anyway breaks the law.Saisei_top_00005

PMDA

PMDA does the examining. A company hands over its quality, safety, and efficacy data. PMDA digs through it. If the product passes, the Minister of MHLW grants marketing approval after expert discussion.0003

PMDA gave an update on 20 May 2026. By that date, 26 regenerative medical products had been approved under the PMD Act.000280868.pdf That number covers cell and tissue products plus gene therapies. About 57.7 percent were cell or tissue-based. About 80.8 percent had orphan status.000280868.pdf Note that the total includes two products that were later withdrawn or expired, so don’t read it as 26 stem cell treatments you can buy today.000280868.pdf

Japan also has a conditional and time-limited approval pathway for qualifying regenerative medical products, based on presumed efficacy and demonstrated safety. Further data collection and a subsequent approval application are required. This is an approval with conditions, not a guarantee of established long-term benefit. 0003

Certified Committees

A clinic cannot just file and go. First a certified regenerative medicine committee has to review the plan. MHLW certifies these committees, and they check the plan against the official standards: safety steps, cell handling, the explanation and consent papers, and follow-up.En

The highest-risk category plays by tougher rules. Only specially qualified committees may review it. MHLW gets up to 90 days from submission to order changes, extendable with notice, and the clinic must wait out that period before starting treatment.En When you read clinic papers, the committee name tells you which outside group looked at the plan.

Cell Processing and Manufacturing

Cell processing is regulated separately from the decision to provide treatment. Facilities fall under permission, certification, or notification depending on what they do, and quality-control requirements apply.En The provision documents should say plainly whether the clinic processes cells itself or hands the job to an outside facility.Plan

For commercial products the jobs split. The manufacturing license comes from the Director-General of the Regional Bureau of Health and Welfare. Marketing authorization comes from the Minister of MHLW. The applications and review work run through PMDA.000277611.pdf You do not need to memorize any of this. Just ask for it in writing. Where are the cells processed, and under which oversight route?

Research Registries

Sometimes cell treatment happens as research. Then the protocol, who can join, what gets measured, and how long patients are followed all go into Japan’s clinical research registry, jRCT.Jrct.mhlw.go.jp A registry entry proves a study was listed with defined methods. It does not say the treatment works.

A provision plan, a processing-facility record and a product approval answer different questions. None replaces evidence about the exact intervention and diagnosis.

Three Risk Classes

The risk class determines the applicable committee-review and submission requirements, rather than creating a separate national regulator for each class. En

Class What it covers Review consequence
Class I Highest-risk uses, where effects on life and health are uncertain or potentially serious even with careful practice; since May 2025 this explicitly includes gene therapy that does not use processed cells Only specially qualified committees may review; MHLW change-order period applies before treatment may start
Class II Middle-risk uses, where careful practice still leaves real risk to life or health Committee review appropriate to Class II and plan submission
Class III Uses that fit neither of the first two groups Standard certified committee review and filing

A lower-risk label never means proven to help.

What Oversight Cannot Promise

A filed provision plan says the clinic finished MHLW’s required admin and review step for a named procedure. It does not prove the treatment works, and it does not cover every condition named on a website.Plan

A PMDA product approval says one specific manufactured product met quality, safety, and efficacy requirements for one defined indication when it was approved, sometimes with conditions and follow-up attached.0003 A privately advertised infusion or injection falls outside that approval unless its exact product and indication match.

Oversight does not remove medical uncertainty. Human evidence should match the disease and stage, patient group, cell source and preparation, dose, route, comparator, outcomes, follow-up and adverse events. A laboratory change alone does not establish improved symptoms, function or survival.

Regulation also never means a cell procedure takes the place of established treatment, emergency care, rehab, or disease monitoring. If anyone suggests putting proven care on hold while trying regenerative medicine, talk that through with the doctor in charge of your overall treatment.

Checks Before You Decide

Consider this document-checking scenario, not a patient case: a quotation says “approved in Japan,” but the attached paper is a provision plan. Ask for the exact plan name, provider, reviewing committee and cell-processing facility, then compare the documents with the official record. If product approval is claimed, ask for the product name and approved indication. This is a practical checking method, not a claim of personal clinical experience. Plan

  1. Get the exact treatment name and its route: a provision plan filed under the safety law, a clinical research protocol, or a manufactured product with PMDA marketing approval.Plan Wording counts here. Two plans that sound alike can hold different status.
  2. Match the papers. The clinic should show the treatment name as listed in the public record, the committee behind the review, the explanation and consent papers, cell source and processing details, session count, follow-up and aftercare, itemized costs, and what happens if there are complications. Read the consent papers before paying anything you cannot get back.
  3. Keep regulatory and clinical questions apart. Who reviewed it? And is there evidence for someone like me? Ask for published human results in your disease and stage, with the same cell type, preparation, dose, and route, plus clear outcomes and follow-up. Animal work, lab findings, and big general claims about regeneration do not count as human proof.
  4. Be clear about who decides. Diagnosis, eligibility, and the treatment call itself belong to the treating physician. Support staff, translators, and coordinators can help with information and appointments. They do not decide whether treatment fits you.

If the answers come back vague about the route, the exact name, or what happens when something goes wrong, stop and get it in writing first.

Not sure which route your treatment falls under?

Send the exact treatment name and the documents you received. The patient support team will help you sort out the regulatory wording before you commit.

Contact the Patient Support Team

MHLW is the lead national authority; PMDA reviews commercial products and certified committees review clinic plans. For a specific offer, identify the exact product or plan and check its current record. A historical approval count does not tell you whether a proposed procedure is appropriate for you.

Sources

  1. PMDA — Regenerative Medical Products (regulatory framework)
  2. MHLW — Laws and notices on regenerative medicine (enforcement dates)
  3. MHLW Regional Bureau — Procedures for submitting provision plans (amendment detail)
  4. MHLW — Overview of provision-plan submission (patient information)
  5. PMDA — Japan’s Regulatory Framework and Recent Updates on Regenerative Medical Products, ARM APAC Forum, 20 May 2026
  6. Japanese Law Translation — Act on the Safety of Regenerative Medicine
  7. PMDA — Manufacturing and Marketing Procedures for Regenerative Medical Products
  8. jRCT — Japan Registry of Clinical Trials (MHLW clinical research registry system)